NeoGraph Analytics
Healthcare ITNorth America2023 – 2032

Global United States Digital Therapeutics Market Size, Share and Trends Analysis

The Digital Therapeutics market is projected to reach $52.0B by 2032, growing at a 26.0% CAGR from $6.5B in 2023.

Revenue, 2023

$6.5B

Forecast, 2032

$52.0B

CAGR, 2024-2032

26%

Report Coverage

North America

Code: united-states-digital-therapeutics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global digital therapeutics market, valued at $6.5 billion in 2023, is projected to reach $52.0 billion by 2032, growing at a 26.0% CAGR. North America leads with 42% share, driven by FDA clearances and rising chronic disease prevalence. Click Therapeutics, Pear Therapeutics, and Akili Interactive are key players. Mental health and substance use disorder segments dominate adoption. Regulatory frameworks and reimbursement pathways are expanding, accelerating clinical integration and commercial scalability of prescription digital therapeutics.

02

Key Highlights

1

Global DTx market projected to reach $52.0B by 2032 at 26.0% CAGR

2

Mental health segment leads with 35% market share in 2023

3

North America commands 42% of global market driven by U.S. FDA frameworks

03

Market Overview

Market Context

Digital therapeutics are software-based medical treatments delivering evidence-based therapeutic interventions for chronic conditions. The market is experiencing rapid growth driven by FDA authorizations, rising chronic disease burden, and expanding payer reimbursement. The U.S. remains the dominant market.

The global DTx market reached $6.5B in 2023 and is forecast to hit $52.0B by 2032 at a 26.0% CAGR. Growth is fueled by FDA authorizations, chronic disease burden, and expanding insurance reimbursement for software-based treatments.

Market Stage

High growth

Adoption Level

Growing

Key Trends

FDA breakthrough device designation accelerating DTx approvalsIntegration of AI and machine learning for personalized therapyPayer reimbursement models expanding for prescription DTxPartnerships between pharma companies and DTx platforms increasingVR/AR-based therapeutic interventions gaining clinical validation
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 26%

Base Year (2023)

$6.5B

Forecast (2032)

$52.0B

CAGR (2024-2032)

26%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$6.50B
2024$8.19B
2025$10.32B
2026$13.00B
2027$16.38B
2028$20.64B
2029$26.01B
2030$32.77B
2031$41.29B
2032$52.03B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The DTx market will grow from $6.5B in 2023 to $52.0B by 2032, reflecting a 26.0% CAGR. Acceleration is driven by increasing clinical validation, pharma partnerships, and favorable regulatory pathways enabling faster market entry for new therapeutic software.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%27.5%United States
Europe30.0%22.0%Germany
Asia Pacific28.0%29.0%China

North America

#1
Share: 42.0%CAGR: 27.5%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 22.0%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising prevalence of chronic diseases and mental health disorders
  • Increasing FDA approvals for prescription digital therapeutics
  • Growing adoption of telehealth and remote patient monitoring
06

Market Segmentation

By Technology
Market share distribution across 4 segments
By Technology — market share by segment, in percent.
SegmentShare
Software-Based TherapeuticsDominant segment comprising standalone prescription and OTC software applications.50.0%
AI-Driven Personalized TherapyAdaptive algorithms personalizing treatment pathways based on real-time patient data.25.0%
VR/AR-Based TherapyImmersive therapeutic environments for pain management, PTSD, and rehabilitation.15.0%
Wearable-Integrated TherapyConnected devices enabling continuous monitoring and just-in-time adaptive interventions.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Therapeutic Area
Market share distribution across 6 segments
By Therapeutic Area — market share by segment, in percent.
SegmentShare
Mental HealthLargest segment driven by CBT-based apps for depression, anxiety, and PTSD with strong clinical evidence.35.0%
Substance Use DisordersFDA-authorized DTx for opioid and alcohol use disorders showing significant patient engagement.20.0%
Diabetes & Metabolic DisordersCBT-based digital interventions for Type 2 diabetes management gaining payer support.15.0%
Cardiovascular DiseasesDigital therapeutics for hypertension, cardiac rehab, and medication adherence growing steadily.12.0%
Respiratory DisordersInhaler-connected and sensor-based DTx for asthma and COPD management expanding rapidly.10.0%
Neurological & OthersEmerging applications in ADHD, insomnia, and chronic pain management.8.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Clinics
  • Pharmacy Chains
  • Homecare Settings
07

Regional Analysis

1

North America

Lead: United States
CAGR: 27.5%Share: 42.0%

Largest market driven by FDA regulatory clarity, high healthcare spending, and early DTx commercialization.

2

Europe

Lead: Germany
CAGR: 22.0%Share: 30.0%

Growing adoption supported by EU MDR framework and national digital health reimbursement pilots.

3

Asia Pacific

Lead: China
CAGR: 29.0%Share: 28.0%

Fastest-growing region driven by massive patient populations, mobile health adoption, and government support.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
55.0%
+26.5%
Germany
21.0%
+22.0%
China
24.0%
+30.5%
08

Competitive Landscape

C

Click Therapeutics

United States

Leader350M

FDA-authorized prescription DTx pioneer partnered with Otsuka for mental health and SUD, backed by major pharma and tech investors.

Leading FDA-authorized prescription DTx company focused on mental health and substance use disorders through its Otsuka-partnered platform.

P

Pear Therapeutics

United States

Challenger120M

Early FDA-authorized DTx company with assets in SUD and insomnia; filed Chapter 11 in 2023 but pipeline remains active.

Pioneering prescription DTx developer with FDA-authorized products for substance use disorder, chronic insomnia, and major depressive disorder.

A

Akili Interactive Labs

United States

Follower

Video game-based ADHD DTx acquired and merged with Virtual Therapeutics to form a larger digital health organization.

Also profiled

B

Better Therapeutics

45M

Digital therapeutics company that launched AspyreRx, the first FDA-authorized CBT-based app for Type 2 diabetes management.

09

Recent Developments

25
2025Click Therapeutics

Received strategic investment from Dassault Systèmes to expand DTx platform capabilities

25
2025Better Therapeutics

Expanded payer coverage for AspyreRx across major U.S. health plans

24
2024Akili Interactive Labs

Acquired and merged with Virtual Therapeutics to form a larger digital health organization

24
2024Pear Therapeutics

Emerged from Chapter 11 restructuring with active pipeline partnerships retained

10

Regulatory Landscape

FDA Breakthrough Device Designation pathway for DTx submissionsFDA Digital Health Pre-Cert Program for streamlined software approvalsCMS reimbursement expansion under Medicare for authorized DTx productsEU Medical Device Regulation (MDR) governing DTx classification in Europe
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

The DTx market offers high-growth potential with a 26% CAGR through 2032, particularly in mental health and chronic disease segments.

Operators

Prioritize FDA authorization and payer partnerships to capture market share in the rapidly expanding prescription digital therapeutics space.

Policymakers

Regulatory frameworks like FDA Breakthrough Device Designation are critical enablers requiring continued modernization.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.